Meeting
2021 Gastrointestinal Cancers Symposium
Phase II study of cabozantinib (cabo) combined with pembrolizumab (pembro) in metastatic or recurrent gastric and gastroesophageal adenocarcinoma (GEC) to overcome resistance to checkpoint inhibitors.
Authors
Farshid Dayyani
University of California Irvine, Division of Hematology/Oncology, Department of Medicine, Orange, CA
Farshid Dayyani , Chloe Thomas , Gwendolyn Ung , Thomas H Taylor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Esophageal and Gastric Cancer
Track
Esophageal and Gastric Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04164979
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr TPS253)
DOI
10.1200/JCO.2021.39.3_suppl.TPS253
Abstract #
TPS253
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.
First Author: Charles S. Fuchs
Poster
2015 ASCO Annual Meeting
Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Charles S. Fuchs
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3.
First Author: Samuel J Klempner
Poster
2020 ASCO Virtual Scientific Program
89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.
First Author: Sarah Verhoeff